Still, these results pave the way for the evaluation of bona fide β3-AR agonists or the preferred use of β-blockers endowed with such β3-AR stimulatory activity in the treatment of autoimmune β1-aabs-induced DCM. The gene discussed is ADRB3; the disease is familial dilated cardiomyopathy.